Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
Martin J Coffey,1 Heleen H DeCory,2 Stephen S Lane31Pharmaceutical Product Development, Bausch and Lomb, Inc, Rochester, NY, USA; 2Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA; 3Associated Eye Care, Stillwater, MN, USAAbstract: The eye has protective barriers (ie...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-02-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | http://www.dovepress.com/development-of-a-non-settling-gel-formulation-of-05-loteprednol-etabon-a12201 |
| _version_ | 1819021723066957824 |
|---|---|
| author | Coffey MJ DeCory HH Lane SS |
| author_facet | Coffey MJ DeCory HH Lane SS |
| author_sort | Coffey MJ |
| collection | DOAJ |
| description | Martin J Coffey,1 Heleen H DeCory,2 Stephen S Lane31Pharmaceutical Product Development, Bausch and Lomb, Inc, Rochester, NY, USA; 2Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA; 3Associated Eye Care, Stillwater, MN, USAAbstract: The eye has protective barriers (ie, the conjunctival and corneal membranes) and defense mechanisms (ie, reflex tearing, blinking, lacrimal drainage) which present challenges to topical drug delivery. Topical ocular corticosteroids are commonly used in the treatment of anterior segment diseases and inflammation associated with ocular surgery, and manufacturers continually strive to improve their characteristics. We describe the development of a novel ophthalmic gel formulation of loteprednol etabonate (LE), a C-20 ester-based corticosteroid with an established safety profile, in the treatment of ocular inflammatory conditions. The new LE gel formulation is non-settling, eliminating the need to shake the product to resuspend the drug, has a pH close to that of tears, and a low preservative concentration. The rheological characteristics of LE gel are such that the formulation is instilled as a drop and transitions to a fluid upon instillation in the eye, yet retains sufficient viscosity to prolong ocular surface retention. The new formulation provides consistent, uniform dosing as evidenced by dose extrusion studies, while pharmacokinetic studies in rabbits demonstrated rapid and sustained exposure to LE in ocular tissues following instillation of LE gel. Finally, results from two clinical studies of LE gel in the treatment of postoperative inflammation and pain following cataract surgery indicate that it was safe and effective. Most patients reported no unpleasant drop sensation upon instillation, and reports of blurred vision were rare.Keywords: loteprednol etabonate, gel, drug delivery, clinical trial, ocular surface |
| first_indexed | 2024-12-21T04:11:38Z |
| format | Article |
| id | doaj.art-5bf698ef283d4c42ac60be0a97a3d826 |
| institution | Directory Open Access Journal |
| issn | 1177-5467 1177-5483 |
| language | English |
| last_indexed | 2024-12-21T04:11:38Z |
| publishDate | 2013-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj.art-5bf698ef283d4c42ac60be0a97a3d8262022-12-21T19:16:27ZengDove Medical PressClinical Ophthalmology1177-54671177-54832013-02-012013default299312Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic dropCoffey MJDeCory HHLane SSMartin J Coffey,1 Heleen H DeCory,2 Stephen S Lane31Pharmaceutical Product Development, Bausch and Lomb, Inc, Rochester, NY, USA; 2Global Medical Affairs, Pharmaceuticals, Bausch and Lomb, Inc, Rochester, NY, USA; 3Associated Eye Care, Stillwater, MN, USAAbstract: The eye has protective barriers (ie, the conjunctival and corneal membranes) and defense mechanisms (ie, reflex tearing, blinking, lacrimal drainage) which present challenges to topical drug delivery. Topical ocular corticosteroids are commonly used in the treatment of anterior segment diseases and inflammation associated with ocular surgery, and manufacturers continually strive to improve their characteristics. We describe the development of a novel ophthalmic gel formulation of loteprednol etabonate (LE), a C-20 ester-based corticosteroid with an established safety profile, in the treatment of ocular inflammatory conditions. The new LE gel formulation is non-settling, eliminating the need to shake the product to resuspend the drug, has a pH close to that of tears, and a low preservative concentration. The rheological characteristics of LE gel are such that the formulation is instilled as a drop and transitions to a fluid upon instillation in the eye, yet retains sufficient viscosity to prolong ocular surface retention. The new formulation provides consistent, uniform dosing as evidenced by dose extrusion studies, while pharmacokinetic studies in rabbits demonstrated rapid and sustained exposure to LE in ocular tissues following instillation of LE gel. Finally, results from two clinical studies of LE gel in the treatment of postoperative inflammation and pain following cataract surgery indicate that it was safe and effective. Most patients reported no unpleasant drop sensation upon instillation, and reports of blurred vision were rare.Keywords: loteprednol etabonate, gel, drug delivery, clinical trial, ocular surfacehttp://www.dovepress.com/development-of-a-non-settling-gel-formulation-of-05-loteprednol-etabon-a12201 |
| spellingShingle | Coffey MJ DeCory HH Lane SS Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop Clinical Ophthalmology |
| title | Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop |
| title_full | Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop |
| title_fullStr | Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop |
| title_full_unstemmed | Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop |
| title_short | Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop |
| title_sort | development of a non settling gel formulation of 0 5 loteprednol etabonate for anti inflammatory use as an ophthalmic drop |
| url | http://www.dovepress.com/development-of-a-non-settling-gel-formulation-of-05-loteprednol-etabon-a12201 |
| work_keys_str_mv | AT coffeymj developmentofanonsettlinggelformulationof05loteprednoletabonateforantiinflammatoryuseasanophthalmicdrop AT decoryhh developmentofanonsettlinggelformulationof05loteprednoletabonateforantiinflammatoryuseasanophthalmicdrop AT laness developmentofanonsettlinggelformulationof05loteprednoletabonateforantiinflammatoryuseasanophthalmicdrop |